中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (12): 1048-1056.doi: 10.35541/cjd.20210561
中国康复医学会皮肤病康复专业委员会 中华医学会皮肤性病学分会光动力治疗研究中心 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组
收稿日期:
2021-08-04
修回日期:
2021-09-25
发布日期:
2021-12-01
通讯作者:
王秀丽;顾恒;陈翔
E-mail:wangxiuli_1400023@tongji.edu.cn;guheng@aliyun.com; chenxiangck@126.com
Chinese Association of Rehabilitation Dermatology; Photodynamic Therapy Research Center, Chinese Society of Dermatology; Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment
Received:
2021-08-04
Revised:
2021-09-25
Published:
2021-12-01
Contact:
Wang Xiuli; Gu Heng;Chen Xiang
E-mail:wangxiuli_1400023@tongji.edu.cn;guheng@aliyun.com; chenxiangck@126.com
摘要: 【摘要】 光线性角化病是一种慢性进行性癌前病变,可进展为皮肤鳞状细胞癌。随着中国患病人数逐渐增多,亟须建立合适的诊断及治疗规范。中国康复医学会皮肤病康复专业委员会、中华医学会皮肤性病学分会联合中国医学装备协会皮肤病与皮肤美容分会组织光线性角化病相关领域部分专家,在国内外文献数据、国际指南和专家临床经验的基础上,结合我国诊疗现状,制定中国光线性角化病临床诊疗专家共识。本共识从光线性角化病的流行病学、发病因素及临床转归、临床表现及分级、诊断及鉴别诊断、治疗策略和患者教育管理等方面进行阐述,诊断方面包含了皮肤镜、反射式共聚焦显微镜和皮肤病理等手段,治疗策略涵盖了常见局部治疗和系统治疗方法,局部治疗包括光动力治疗、外用药物、物理治疗和手术切除,且按照证据等级给予推荐级别,为皮肤科医师诊疗工作提供参考。
中国康复医学会皮肤病康复专业委员会 中华医学会皮肤性病学分会光动力治疗研究中心 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. [开放获取] 中国光线性角化病临床诊疗专家共识(2021)[J]. 中华皮肤科杂志, 2021,54(12):1048-1056. doi:10.35541/cjd.20210561
Chinese Association of Rehabilitation Dermatology, Photodynamic Therapy Research Center, Chinese Society of Dermatology, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Expert consensus on clinical diagnosis and treatment of actinic keratosis in China(2021)[J]. Chinese Journal of Dermatology, 2021, 54(12): 1048-1056.doi:10.35541/cjd.20210561
[1] | Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma[J]. J Clin Invest, 2012,122(2):464⁃472. doi: 10.1172/JCI57415. |
[2] | Olsen EA, Abernethy ML, Kulp⁃Shorten C, et al. A double⁃blind, vehicle⁃controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck[J]. J Am Acad Dermatol, 1991,24(5 Pt 1):738⁃743. doi: 10.1016/0190⁃9622(91)70113⁃g. |
[3] | Lee JH, Kim YH, Han KD, et al. Incidence of actinic keratosis and risk of skin cancer in subjects with actinic keratosis: a population⁃based cohort study[J]. Acta Derm Venereol, 2018,98(3):382⁃383. doi: 10.2340/00015555⁃2854. |
[4] | 涂庆峰, 吕婷, 赖永贤, 等. 上海市某社区老年人皮肤肿瘤流行病学研究[J]. 老年医学与保健, 2013,19(3):142⁃145,148. doi: 10.3969/j.issn.1008⁃8296.2013⁃05. |
[5] | Zhao Y, Li CY, Wen CM, et al. The prevalence of actinic keratosis in patients visiting dermatologists in two hospitals in China[J]. Br J Dermatol, 2016,174(5):1005⁃1010. doi: 10.1111/ bjd.14344. |
[6] | Ferrándiz C, Plazas MJ, Sabaté M, et al. Prevalence of actinic keratosis among dermatology outpatients in Spain[J]. Actas Dermosifiliogr, 2016,107(8):674⁃680. doi: 10.1016/j.ad.2016. 05.016. |
[7] | Fargnoli MC, Altomare G, Benati E, et al. Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics[J]. Eur J Dermatol, 2017,27(6):599⁃608. doi: 10.1684/ejd.2017.3126. |
[8] | Reinehr C, Bakos RM. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects[J]. An Bras Dermatol, 2019,94(6):637⁃657. doi: 10.1016/j.abd.2019.10.004. |
[9] | Butani AK, Arbesfeld DM, Schwartz RA. Premalignant and early squamous cell carcinoma[J]. Clin Plast Surg, 2005,32(2):223⁃235. doi: 10.1016/j.cps.2004.11.001. |
[10] | Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971⁃1974[J]. Arch Dermatol, 1988,124(1):72⁃79. |
[11] | de Oliveira E, da Motta V, Pantoja PC, et al. Actinic keratosis ⁃ review for clinical practice[J]. Int J Dermatol, 2019,58(4):400⁃407. doi: 10.1111/ijd.14147. |
[12] | Flohil SC, van der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study[J]. J Invest Dermatol, 2013,133(8):1971⁃1978. doi: 10.1038/jid.2013.134. |
[13] | Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective[J]. Dermatol Ther (Heidelb), 2015,5(1):19⁃35. doi:10.1007/s13555⁃ 015⁃0070⁃9. |
[14] | Ulrich C, Jürgensen JS, Degen A, et al. Prevention of non⁃melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case⁃control study[J]. Br J Dermatol, 2009,161 Suppl 3:78⁃84. doi: 10.1111/j.1365⁃2133.2009.09453.x. |
[15] | Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial[J]. Cancer, 2009,115(11):2523⁃2530. doi: 10.1002/cncr.24284. |
[16] | Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment. A patient⁃oriented perspective[J]. Arch Dermatol, 1991,127(7):1029⁃1031. |
[17] | Lopes ML, Silva Júnior FL, Lima KC, et al. Clinicopathological profile and management of 161 cases of actinic cheilitis[J]. An Bras Dermatol, 2015,90(4):505⁃512. doi: 10.1590/abd1806⁃4841.20153848. |
[18] | de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists′ guidelines for the care of patients with actinic keratosis 2017[J]. Br J Dermatol, 2017,176(1):20⁃43. doi: 10.1111/bjd.15107. |
[19] | Vatve M, Ortonne JP, Birch⁃Machin MA, et al. Management of field change in actinic keratosis[J]. Br J Dermatol, 2007,157 Suppl 2:21⁃24. doi: 10.1111/j.1365⁃2133.2007.08268.x. |
[20] | Huerta⁃Brogeras M, Olmos O, Borbujo J, et al. Validation of dermoscopy as a real⁃time noninvasive diagnostic imaging technique for actinic keratosis[J]. Arch Dermatol, 2012,148(10):1159⁃1164. doi: 10.1001/archdermatol.2012.1060. |
[21] | Yang X, Hu C, Wen L, et al. Dermoscopic monitoring for treatment and follow⁃up of actinic keratosis with 5⁃aminolaevulinic acid photodynamic therapy[J]. Technology in Cancer Research & Treatment, 2018, 17(3): 153 303381882009. doi:10.1177/1533033818820091. |
[22] | Zalaudek I, Piana S, Moscarella E, et al. Morphologic grading and treatment of facial actinic keratosis[J]. Clin Dermatol, 2014,32(1):80⁃87. doi: 10.1016/j.clindermatol.2013.05.028. |
[23] | 中国医疗保健国际交流促进会皮肤科分会皮肤影像学组, 中华医学会皮肤性病学分会皮肤病数字化诊断亚学组, 中国中西医结合学会皮肤性病专业委员会皮肤影像学组, 等. 鳞状细胞肿瘤皮肤镜特征专家共识(2017)[J]. 中华皮肤科杂志, 2018,51(2):87⁃91. doi: 10.3760/cma.j.issn.0412⁃4030.2018.02. 001. |
[24] | Papageorgiou C, Lallas A, Manoli SM, et al. Evaluation of dermatoscopic criteria for early detection of squamous cell carcinoma arising on an actinic keratosis[J]. J Am Acad Dermatol, 2021:S0190⁃9622(21)00760⁃X. doi: 10.1016/j.jaad.2021.03.111. |
[25] | Jin Q, Li W, Wu W, et al. Assessment of 5⁃aminolaevulinic acid photodynamic therapy (ALA⁃PDT) in Chinese patients with actinic keratosis: correlation of dermoscopic features with histopathology[J]. Australas J Dermatol, 2020,61(3):e339⁃e343. doi: 10.1111/ajd.13289. |
[26] | Prow TW, Tan JM, Pellacani G. Reflectance confocal microscopy: hallmarks of keratinocyte cancer and its precursors[J]. Curr Probl Dermatol, 2015,46:85⁃94. doi: 10.1159/00036 6541. |
[27] | 刘峰, 刘刚, 徐丽敏, 等. 运用共聚焦激光扫描显微镜在术前测定日光性角化病边界的效果分析[J]. 中国皮肤性病学杂志, 2014,28(3):263⁃265+268. |
[28] | Nguyen KP, Peppelman M, Hoogedoorn L, et al. The current role of in vivo reflectance confocal microscopy within the continuum of actinic keratosis and squamous cell carcinoma: a systematic review[J]. Eur J Dermatol, 2016,26(6):549⁃565. doi: 10.1684/ejd.2016.2872. |
[29] | 吴秀娟, 向芳, 赵宗峰, 等. 反射式共聚焦扫描显微镜在日光性角化病诊断中的应用[J]. 中国麻风皮肤病杂志, 2016,32(5):267⁃269. |
[30] | Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis")[J]. J Am Acad Dermatol, 2000,42(1 Pt 2):11⁃17. doi: 10.1067/mjd.2000.103344. |
[31] | McKee P, Calonje E, Granter S, et al. 皮肤病理学: 与临床的联系[M]. 朱学骏, 孙建方, 译. 3版. 北京: 北京大学医学出版社, 2007:1187⁃1192. |
[32] | Roewert⁃Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis ⁃ an update[J]. Br J Dermatol, 2007,157 Suppl 2:18⁃20. doi: 10.1111/j.1365⁃2133. 2007.08267.x. |
[33] | Wong TH, Morton CA, Collier N, et al. British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018[J]. Br J Dermatol, 2019,180(4):730⁃739. doi: 10.1111/bjd.17309. |
[34] | Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF⁃200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double⁃blind, placebo⁃controlled phase III study[J]. Br J Dermatol, 2010,163(2):386⁃394. doi: 10.1111/j.1365⁃2133.2010.09873.x. |
[35] | 中华医学会皮肤性病学分会光动力治疗研究中心, 中国康复医学会皮肤病康复专业委员会, 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法皮肤科临床应用指南(2021版)[J]. 中华皮肤科杂志, 2021,54(1):1⁃9. doi: 10.35541/cjd.20200731. |
[36] | Zhu L, Wang P, Zhang G, et al. Conventional versus daylight photodynamic therapy for actinic keratosis: a randomized and prospective study in China[J]. Photodiagnosis Photodyn Ther, 2018,24:366⁃371. doi: 10.1016/j.pdpdt.2018.10.010. |
[37] | Cai H, Wang YX, Sun P, et al. Photodynamic therapy for facial actinic keratosis: a clinical and histological study in Chinese patients[J]. Photodiagnosis Photodyn Ther, 2013,10(3):260⁃265. doi: 10.1016/j.pdpdt.2012.12.003. |
[38] | Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12⁃month follow up[J]. Br J Dermatol, 2006,155(6):1262⁃1269. doi: 10.1111/j.1365⁃2133.2006.07520.x. |
[39] | Jansen M, Kessels J, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis[J]. N Engl J Med, 2019,380(10):935⁃946. doi: 10.1056/NEJMoa1811850. |
[40] | Zhang L, Zhao Z, Wang P, et al. Long⁃term improvement on photoaging after ALA photodynamic therapy for actinic keratosis: a retrospective study[J]. Photodiagnosis Photodyn Ther, 2021,33:102181. doi: 10.1016/j.pdpdt.2021.102181. |
[41] | Chen J, Zhang Y, Wang P, et al. Plum⁃blossom needling promoted PpIX fluorescence intensity from 5⁃aminolevulinic acid in porcine skin model and patients with actnic keratosis[J]. Photodiagnosis Photodyn Ther, 2016,15:182⁃190. doi: 10.1016/j.pdpdt.2016.06.012. |
[42] | Zheng Z, Zhang LL, Shi L, et al. What is the most relevent factor causing pain during ALA⁃PDT? A multi⁃center, open clinical pain score research trial of actinic keratosis, acne and condylomata acuminata[J]. Photodiagnosis Photodyn Ther, 2019,26:73⁃78. doi: 10.1016/j.pdpdt.2019.03.001. |
[43] | Ibbotson SH, Wong TH, Morton CA, et al. Adverse effects of topical photodynamic therapy: a consensus review and approach to management[J]. Br J Dermatol, 2019,180(4):715⁃729. doi: 10.1111/bjd.17131. |
[44] | Dréno B, Amici JM, Basset⁃Seguin N, et al. Management of actinic keratosis: a practical report and treatment algorithm from AKTeam™ expert clinicians[J]. J Eur Acad Dermatol Venereol, 2014,28(9):1141⁃1149. doi: 10.1111/jdv.12434. |
[45] | Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double⁃blind, vehicle⁃controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses[J]. Arch Dermatol, 2002,138(11):1498⁃1502. doi: 10.1001/archderm.138. 11.1498. |
[46] | Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double⁃blind, vehicle⁃controlled, clinical trial with histology[J]. J Am Acad Dermatol, 2004,51(4):547⁃555. doi: 10.1016/j.jaad.2004.02.022. |
[47] | Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double⁃blind, placebo⁃controlled studies[J]. J Drugs Dermatol, 2013,12(11):1278⁃1282. |
[48] | 王宏伟, 王秀丽, 过明霞. 外用咪喹莫特乳膏致局限型白癜风二例[J]. 中华皮肤科杂志, 2006,39(10):613. doi: 10.3760/j.issn:0412⁃4030.2006.10.029. |
[49] | Segatto MM, Dornelles SI, Silveira VB, et al. Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5⁃fluorouracil[J]. An Bras Dermatol, 2013,88(5):732⁃738. doi: 10.1590/abd1806⁃4841.20132083. |
[50] | Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis[J]. Int J Dermatol, 2020,59(6):677⁃684. doi: 10.1111/ijd.14767. |
[51] | Werner RN, Jacobs A, Rosumeck S, et al. Methods and results report ⁃ evidence and consensus⁃based (S3) guidelines for the treatment of actinic keratosis ⁃International League of Dermatological Societies in cooperation with the European Dermatology Forum[J]. J Eur Acad Dermatol Venereol, 2015,29(11):e1⁃e66. doi: 10.1111/jdv.13179. |
[52] | Walker JL, Siegel JA, Sachar M, et al. 5⁃Fluorouracil for actinic keratosis treatment and chemoprevention: a randomized controlled trial[J]. J Invest Dermatol, 2017,137(6):1367⁃1370. doi: 10.1016/j.jid.2016.12.029. |
[53] | Stough D, Bucko AD, Vamvakias G, et al. Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: an 18⁃month open⁃label study[J]. Cutis, 2010,85(5):267⁃273. |
[54] | Hoover WD 3rd, Jorizzo JL, Clark AR, et al. Efficacy of cryosurgery and 5⁃fluorouracil cream 0.5% combination therapy for the treatment of actinic keratosis[J]. Cutis, 2014,94(5):255⁃259. |
[55] | Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and safety of 5⁃fluorouracil 0.5%/salicylic acid 10% in the field⁃directed treatment of actinic keratosis: a phase iii, randomized, double⁃blind, vehicle⁃controlled trial[J]. Dermatol Ther (Heidelb), 2017,7(1):81⁃96. doi: 10.1007/s13555⁃016⁃0161⁃2. |
[56] | Ulrich M, Reinhold U, Falqués M, et al. Use of reflectance confocal microscopy to evaluate 5⁃fluorouracil 0.5%/salicylic acid 10% in the field⁃directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double⁃blind, vehicle⁃controlled trial[J]. J Eur Acad Dermatol Venereol, 2018,32(3):390⁃396. doi: 10.1111/jdv.14611. |
[57] | Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel[J]. Br J Dermatol, 2002,146(1):94⁃100. doi: 10.1046/j.1365⁃2133.2002. 04561.x. |
[58] | Akarsu S, Aktan S, Atahan A, et al. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses[J]. Clin Exp Dermatol, 2011,36(5):479⁃484. doi: 10.1111/j.1365⁃2230.2010.03999.x. |
[59] | Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial[J]. J Am Acad Dermatol, 2003,49(1):83⁃90. doi: 10.1067/mjd.2003.451. |
[60] | Ianhez M, Pinto SA, Miot HA, et al. A randomized, open, controlled trial of tretinoin 0.05% cream vs. low⁃dose oral isotretinoin for the treatment of field cancerization[J]. Int J Dermatol, 2019,58(3):365⁃373. doi: 10.1111/ijd.14363. |
[61] | Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses[J]. Int J Dermatol, 2004,43(9):687⁃692. doi: 10.1111/j.1365⁃4632.2004. 02056.x. |
[62] | Zane C, Facchinetti E, Rossi MT, et al. Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial[J]. Br J Dermatol, 2014,170(5):1114⁃1121. doi: 10.1111/bjd. 12847. |
[63] | Ianhez M, Fleury LF Jr, Miot HA, et al. Retinoids for prevention and treatment of actinic keratosis[J]. An Bras Dermatol, 2013,88(4):585⁃593. doi: 10.1590/abd1806⁃4841.20131803. |
[64] | de Sévaux RG, Smit JV, de Jong EM, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin[J]. J Am Acad Dermatol, 2003,49(3):407⁃412. doi: 10.1067/s0190⁃9622(03)01831⁃0. |
[65] | 中国医师协会皮肤科医师分会皮肤美容事业发展工作委员会. 皮肤防晒专家共识(2017)[J]. 中华皮肤科杂志, 2017,50(5):316⁃320. doi:10.3760/cma.j.issn.0412⁃4030.2017.05.002. |
[1] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国中西医结合学会皮肤性病专业委员会 . [开放获取] 中国化学剥脱术临床应用专家共识(公众版2024版)[J]. 中华皮肤科杂志, 2024, 0(5): 20230620-e20230620. |
[2] | 《乳房外Paget病诊治专家共识(版)》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识(2024版)[J]. 中华皮肤科杂志, 2024, 57(5): 400-408. |
[3] | 中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南(2024版)[J]. 中华皮肤科杂志, 2024, 57(5): 387-399. |
[4] | 中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟 中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识(2024版)[J]. 中华皮肤科杂志, 2024, 57(5): 426-434. |
[5] | 中国医师协会皮肤科医师分会 中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识(2024版)[J]. 中华皮肤科杂志, 2024, 57(5): 409-417. |
[6] | 中国中西医结合学会皮肤性病学分会真菌学组 中国耐药皮肤癣菌病诊治与防控工作组. [开放获取] 中国耐药皮肤癣菌感染诊治与防控专家共识(2024版)[J]. 中华皮肤科杂志, 2024, 57(5): 418-425. |
[7] | 葛新红 马迎东 焦亚宁 刘玲玲 周镁 紫薇 李博文. 532 nm皮秒激光治疗面部早期脂溢性角化病的疗效和安全性分析[J]. 中华皮肤科杂志, 2024, 57(4): 359-362. |
[8] | 杨玉婷 顾国林 吴敏娟 盛志杰 李晋 莫星帆 吴敏智 胥萍. 血清纤维连接蛋白联合梅毒非特异性抗体检测在梅毒血清固定患者中排除无症状神经梅毒的初步探讨[J]. 中华皮肤科杂志, 2024, 57(3): 246-249. |
[9] | 中国医学科学院皮肤病医院 中国疾病预防控制中心性病控制中心 中华医学会皮肤性病学分会性病学组 中国康复医学会皮肤病康复专业委员会. [开放获取] 中国生殖支原体感染诊疗专家共识(2024)[J]. 中华皮肤科杂志, 2024, 57(3): 201-208. |
[10] | 谢琳 陈锐 牛建军 杨天赐. 新型神经梅毒诊断标志物UCH-L1、GFAP和NF-L与传统神经梅毒检测指标的诊断效能比较[J]. 中华皮肤科杂志, 2024, 57(3): 224-232. |
[11] | 陈娜娜 李峥 张杰 李世慎 李伟. 南宁市147例隐性梅毒患者中早期感染情况的横断面调查[J]. 中华皮肤科杂志, 2024, 57(3): 213-217. |
[12] | 中华医学会皮肤性病学分会 中国疾病预防控制中心性病控制中心 中国医师协会皮肤科医师分会 中国康复医学会皮肤病康复专业委员会. 中国沙眼衣原体泌尿生殖道感染临床诊疗指南(2024)[J]. 中华皮肤科杂志, 2024, 57(3): 193-200. |
[13] | 严可心 张韡 宋昊 徐秀莲. 纳米医学在恶性黑色素瘤中的诊断和治疗新策略[J]. 中华皮肤科杂志, 2024, 0(3): 20230109-e20230109. |
[14] | 王煜坤 刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660. |
[15] | 陈立新 王莹 高西波 秦蓓 李钦峰. 儿童经典型和色素减退型扁平疣反射式共聚焦显微镜特征及与组织病理的对应关系初探[J]. 中华皮肤科杂志, 2024, 57(3): 249-253. |
|